Drugs / Micronized progesterone
Micronized progesterone
also known as
Utrogestan · Crinone 8% · m-P · micronised progesterone · MVP · progesterone · Prometrium · utrogestran
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07173361 | Jan → May 2026 | — | McMaster University | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04225221 | Feb 2020 → Apr 2022 | bulimia nervosa | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT04051320 | Jan 2020 → Jul 2022 | postpartum depression | University of North Carolina, Chapel Hill | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT02989519 | Aug 2015 → Jan 2017 | — | Sanpasitthiprasong Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01850030 | Aug 2013 → Mar 2016 | female infertility | Abbott | Completed | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT03976544 | May 2019 → Jan 2025 | pregnancy disorder with abortive outcome | CRG UZ Brussel | Terminated | Met primary |
| Phase 4 | NCT03677336 | May 2019 → Aug 2020 | female infertility, male reproductive system disorder | CRG UZ Brussel | Completed | No outcome recorded |
| Phase 4 | NCT03436303 | Feb 2014 → Jun 2018 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00755963 | May 2009 → Jul 2011 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable7 trials · 1 missed | ||||||
| — | NCT07496294 | Apr 2026 → Oct 2027 expected | — | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06715514 | Feb 2025 → Dec 2026 expected | type 2 diabetes mellitus | Lia Bally | Recruiting | No outcome recorded |
| — | NCT07307092 | Oct 2021 → Apr 2022 | cervical incompetence | Hina Mukhtar | Completed | No outcome recorded |
| — | NCT04108039 | Sep 2019 → Jan 2022 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| — | NCT02329535 | Jan 2015 → Aug 2017 | — | HaEmek Medical Center, Israel | Terminated | No outcome recorded |
| — | NCT02086032 | Jan 2014 → Jun 2015 | — | Chiang Mai University | Completed | No outcome recorded |
| — | NCT01046708 | Sep 2008 → Aug 2009 | infertility disorder | University Hospital Brussels | Completed | Missed primary |
| Comparator or background therapy15 trials | ||||||
| Phase 0 | NCT04597099 Background | Oct 2022 → Oct 2025 | polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| Phase 0 | NCT03068910 Background | Jul 2016 → Oct 2025 overdue | polycystic ovary syndrome | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT07010146 Background | Oct 2025 → Dec 2029 expected | bone remodeling disease, functional hypothalamic amenorrhea | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT02677259 Background | May 2016 → Jun 2018 | — | One Fertility | Unknown | No outcome recorded |
| Phase 3 | NCT05586724 Comparator | Mar 2022 → Sep 2026 overdue | — | Angelica Lindén Hirschberg | Recruiting | No outcome recorded |
| Phase 4 | NCT06834594 Comparator | Jul 2025 → Jul 2026 overdue | Turner syndrome | Children's Mercy Hospital Kansas City | Recruiting | No outcome recorded |
| Phase 4 | NCT05997563 Comparator | Aug 2023 → Aug 2025 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT04992468 Background | Oct 2021 → Apr 2023 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT04758871 Comparator | Oct 2021 → Sep 2023 | female infertility | CRG UZ Brussel | Completed | No outcome recorded |
| Phase 4 | NCT04719000 Background | Feb 2021 → Aug 2027 expected | infertility disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 4 | NCT03642665 Comparator | Sep 2018 → Nov 2024 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02571296 Comparator | Jul 2015 → Apr 2016 | — | Ghamra Military Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00154180 Comparator | Sep 2005 → May 2012 | arteriosclerosis disorder | Kronos Longevity Research Institute | Unknown | No outcome recorded |
| — | NCT03998761 Comparator | Jun 2019 → Jan 2021 | infertility disorder | My Duc Hospital | Completed | No outcome recorded |
| — | NCT02524561 Comparator | Sep 2005 → Dec 2013 | breast disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-03-09 | Xiromed LLC | Xiromed LLC Launches Melphalan Vial for Injection and Progesterone Capsules xiromed.com ↗ |
| 2012-03-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Prometrium® Capsules in the United States tevapharm.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | micronized progesterone | “Participants are randomized into three groups, the CEE 0.3 mg/micronized progesterone (MP) 100 mg group; CEE 0.625 mg/MP 100 mg group; CEE 0.625 mg/dydrogesterone 10 mg...” NCT03436303 ↗30“Micronized progesterone 400 mg suppository administered rectally once daily from 16 to 36 weeks of gestation following cervical cerclage. Intended to provide sustained...” NCT07307092 ↗ “Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime” NCT02524561 ↗ “with 200 mg micronized progesterone given for 12 days of every month” NCT07010146 ↗ “Utrogestan®*: once daily 200mg of micronized progesterone” NCT06715514 ↗ “micronized progesterone 90 mg (Crinone 8% ® - Merck)” NCT04719000 ↗ “Micronized progesterone 200mg (Utrogestan®)” NCT04992468 ↗ |
| Known as | Crinone 8% | “micronized progesterone 90 mg (Crinone 8% ® - Merck)” NCT04719000 ↗ |
| Known as | m-P | “0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micronized progesterone (m-P) for the first 12 d of each month” PMID 26035291 ↗ Jun 2015 |
| Known as | micronised progesterone | “Data suggest that micronised progesterone (mP) in menopausal hormone therapy is safer for the breast than synthetic progestins” PMID 39448218 ↗ Oct 2024 |
| Known as | MVP | “micronized vaginal progesterone (MVP) 600 mg daily” PMID 28333318 ↗ May 2017 |
| Known as | progesterone | “oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission” NCT04597099 ↗ |
| Known as | Prometrium | “Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime” NCT02524561 ↗ |
| Known as | Utrogestan | “Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm.” NCT03642665 ↗4“Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)” NCT05586724 ↗ “Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation” NCT02329535 ↗ “Micronized progesterone 200mg (Utrogestan®)” NCT04992468 ↗ “Utrogestan” NCT02989519 ↗ |
| Known as | utrogestran | “The first group also received dydrogesterone (duphaston®) at 10 mg and the second group micronized progesterone (utrogestran®) at 100 mg.” PMID 28609128 ↗ Jun 2017 |
| Action | Inhibit | “endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg)” NCT04108039 ↗ |
| Route | Oral | “Women in the active treatment groups also received oral 200 mg/d micronized progesterone the first 12 days of the month” PMID 32520900 ↗ Aug 2020 |